OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Gene therapy group Oxford BioMedica said it had received a Special Protocol Assessment agreement from the FDA. The agreement was made for a phase III trial of TroVax, its renal cell carcinoma treatment and paves the way for the start of the trial in the second of this year. Meanwhile, discussions are ongoing with regards to trials in Europe. The shares ended the final session of the week 1.25p lower at 29.25p.

KD.

anyone bought rgt, news looks good

OAK -It's probably EVO manipulating the SP.

Expect some huge buying of OXB at this price, it's been the target for the institutions to trade back to 35-40 and starts here, a licence deal is around the corner and there is at least one large Pharmaceutical co eyeing them up. Trial in Europe will also be announced shortly...

I certainly hope so robstuff. I've tucked these away for the best part of 3 years now and it's been depressing to see them meander back to the price I bought them at but I still believe so I hope you're right!

More excellent news - overlooked by the market but adds value.

Broadly positive news released on Monday. I guess the second part of the message may account for the recent decline in sp but there appear to be a number of irons in the fire regarding a potential partner which bodes well going forward:

Oxford, UK - 31 July 2006: Oxford BioMedica today issues an update on TroVax, the Company's leading cancer immunotherapy product. The update provides information on progress with clinical trial programmes and a marketing partner deal for TroVax.

The Board is pleased to confirm that the TroVax clinical development plan is on
track with appropriate regulatory submissions being made and trial centres for
the phase III TRIST study being set up in the US and Western and Eastern Europe.
Other product development programmes are also progressing according to plan. A
full update will be given with the Company's interim results on 5 September 2006.

A number of shareholders have asked for information on progress towards a TroVax
deal. The Company is in active discussions with a number of potential commercial
partners for TroVax. Inevitably those discussions are highly sensitive. All the
potential partners are substantial companies and have the capability to support
the Company's plans for TroVax and the successful marketing of this product.

Clarification as regards Therion Biologics

The Company has noted some speculation in the market that the failure of
clinical trials of PANVAC-VF, developed by the privately owned United States
company, Therion Biologics, might suggest that phase III trials of TroVax will
not be successful.


Although the Directors do not have access to detailed information on the
PANVAC-VF study, they wish to make the following comments:

While PANVAC-VF uses a similar viral delivery system to TroVax, the active
antigenic components of TroVax are completely different to those used in
PANVAC-VF. PANVAC-VF comprises CEA and Muc-1 whereas TroVax comprises the Company's proprietary antigen, 5T4.
The PANVAC-VF phase III study was in pancreatic cancer patients who had
already failed chemotherapy. This is a particularly challenging target where
no product has shown a survival benefit. In the case of a vaccine the
problem is that the patients' disease advances significantly before a strong
immune response has time to be established by the product. The planned
TroVax phase III TRIST trial is in advanced renal cell cancer patients who
will have received no prior therapy for their metastatic disease and who
have a median survival, with current care, of about 12 months. As has been
shown in a number of phase I/II and phase II studies of TroVax, this is
ample time for an immune response to be established.

In summary, the Directors do not believe that data from the PANVAC-VF trial have
a significant bearing on the future of TroVax.

Good daily movement upwards - anyone have an opinion as to why?

Oxford BioMedica expects to commence patient recruitment in its Phase III trial in RCC, designated as TRIST (TroVax Renal Immunotherapy Survival Trial), during the second half of 2006. Oxford BioMedica has a Special Protocol Assessment agreement from the US Food and Drug Administration for the TRIST study. Further trials are also planned in colorectal cancer and other cancer types.

Taken from : Oxford Bio's website

http://www.oxfordbiomedica.co.uk/news/2006-ob-17.htm

Thanks - you too are "One2Watch" !!

Just this last week we hear a great story where a father survived cancer and saw his daughter married. Great story and it was down to gene-therapy.
All good so far.
However, this has pushed up the price of OXB - yippee!
Except it was nothing to do with OXB - and importantly the "news" was almost a year old - the guy survived and his daughter is already married......so I fail to understand why the market is suddenly excited - sure it gives some credence to gene-therapy......well, except in the trial 80% of the patients died.....this guy and (I think one other survived - buit that's part of the mystery ).
Maybe he has just died but the "human-interest" story is being touted to gain funding for the US-university-labs. It's very odd...Why now?
Why wasn't this story on the newswire when the daughter got married in September 2005? That's what's really odd.
So, Dunno, but it ain't OXB
(Indeed one might think that this shows there is likely to be competition in the prime market....oh dear.)...and their news is a year (at least) ahead. I hold

from what I remeber it was also on the news on Channel 4 on Friday evening.

I think you will find that there has/is/will be a presentation in USA although no RNS as yet

they used OXBs technology to deliver the protein to the cells, this is the reason for the news to affect OXB

I don't think there was any use of "Oxford's technology" - where did you gleen this, robstuff?
Certainly it was "Gene therapy" but OXB doesn't own the whole lot, there are plenty of competing alternatives within the range of gene therapy... almost as many as there are genes.
The point of OXB's therapy is that the cell is one that mankind has lived with, without any recorded side-effects. Nevertheless OXB has to go through the full phase-trials, like anyone else.
The American trials whilst newsworthy (I presume) were over a year ago and it is curious that the story should come out just a few days before OXB is about to report (early Sept06, so I understand) - and is in the process of negotiating a partner that is likely to be US-based.
This (news item) couldn't have come at a better time, despite it's wholly disconnected from OXB, other than it used Gene therapy.
( I understand the story was reported on SKY, Ch5 and maybe Ch4., but it all went quiet within a short time....)
+Good luck to OXB but I would prefer my investment to be judged on PhIII trial facts rather than media excitement.
Please DYOR, this area is very complicated and the rewards are (we understand) considerable.

Anyone know what has stirred this one up this morning

Do you mean apart from the buy of 8,301,417? (9:54)

That's a fairly big spoon.

Others will follow in case they miss out!

Red

Hi Red - sorry yes it was the large buy (and a very odd amount) that caught me interest.

Ou est tout le monde?

Ya what mate